BioPharma Credit PLC (LSE:BPCP) published its half-year report on 24 September 2026, covering a period in which it committed more than US$700 million to new loans while holding a large cash balance. It also recorded a narrower discount to Net Asset Value (NAV) and a planned change of chair. The central question is how the company's lending activity and results shape its position as a specialist lender to the life sciences industry.

A specialist lender to life sciences companies

BioPharma Credit is a closed-ended Investment company listed on the London Stock Exchange's Main Market, with its shares quoted in both US dollars and sterling. It provides Debt Financing to life sciences companies, and its portfolio is largely made up of senior secured loans to businesses in the sector. The investment manager is Pharmakon Advisors, LP, whose chief executive and co-founder is Pedro Gonzalez de Cosio. The company reports in US dollars, and its NAV and dividends are stated in that currency.

According to the half-year report, 51% of its loans carried floating rates and 49% fixed rates, and the company limits exposure to any single borrower to no more than 25% of gross assets.

Results for the six months to 30 June 2026

The company reported a return after finance costs and tax of US$50.4 million and Net Income of US$0.0447 per share. NAV per share was US$1.0148 at 30 June, compared with US$1.0192 at 31 December 2025, and total net Assets were US$1,138.8 million. The US dollar share price rose from US$0.9160 to US$0.9540, and the discount to NAV narrowed from 10.1% to 6.0%.

Dividends paid during the half totalled 4.95 US cents per share, and the company declared a further 1.75 cents for the second quarter. Under its discount control mechanism, it repurchased 7.0 million shares at an average price of US$0.95, at a total cost of US$6.7 million.

New loans, exits and cash

New commitments during the half totalled US$716.3 million across seven investments, including senior secured loans of US$150.0 million to Mineralys, US$125.0 million to Zenas, US$120.0 million to Esperion and US$92.8 million to Idorsia, as well as refinancings for Paratek and UroGen. After the period end, on 10 July, it committed US$45.0 million to Kestra.

The company also recorded realisations. It received a US$37.1 million prepayment from Alphatec and completed the sale of Lumira on 14 August, recovering "approximately 101%. of its principal investment". At 30 June, cash represented 22.9% of net assets, or US$260.1 million. The single largest Loan exposure was to Insmed, at 19.1% of net assets.

Governance and outlook

The report confirmed that chairman Harry Hyman will step down at the end of 2026, with Rolf Soderstrom to succeed him. Graeme Proudfoot joined the board on 15 September 2026. The manager said it expects "that our new investment pipeline will continue to be strong", pointing to sustained Capital needs as the number of Clinical Trials grows.

Risks to watch

The portfolio remains relatively concentrated in a limited number of borrowers, so the credit performance of individual companies matters. Early repayments can return capital ahead of schedule, requiring reinvestment, and the company holds a substantial cash balance that may earn less than its loans. Changes in interest rates affect income on the floating-rate portion, and Exchange Rate movements influence returns for sterling-based holders of the BPCP line. The report itself acknowledged that the global economic outlook "remains uncertain".

Conclusion

The 24 September half-year report shows a company that increased its lending to the life sciences sector, maintained quarterly dividends and bought back shares, while its NAV per share was broadly stable and its discount narrowed. The pace at which it deploys its cash, and the credit quality of its larger borrowers, are likely to shape its next set of results.